IP Library Granted Patent US 10,072,079
Granted Patent B2
US 10,072,079 · App. 14/959,784 · Granted Sep 11, 2018

Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3

Inventor: Armin Ehninger (Dresden, DE)
Assignee: GEMoaB Monoclonals GmbH
C07K16/2809A61K35/28C07K16/2803C12N5/0663C07K2317/31C07K2317/76C12N2510/00C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,072,079
App. No.
14/959,784
Granted
Sep 11, 2018
Kind
B2
Abstract

The invention concerns pluri- or multipotent stem cells (SCs), e.g. human pluri- or multipotent stem cells (hSCs) engineered to express a multispecific antibody and which further express, on their surface, a human immune cell co-stimulatory ligand or an active fragment thereof.

Claims (9)

1. An isolated human mesenchymal stem cell (MSC) comprising:

i) a nucleic acid sequence encoding a bispecific antibody comprising a variable light (V L ) antibody domain and variable heavy (V H ) antibody domain that specifically bind to CD33 and a V L antibody domain and V H antibody domain that specifically bind to CD3, and

ii) a nucleic acid sequence encoding 4-1BB ligand,

wherein said MSC expresses and secretes a bispecific antibody capable of specifically binding to CD33 and CD3, and

wherein said MSC expresses 4-1BB ligand capable of being a human T-cell co-stimulatory ligand.

2. The isolated MSC of claim 1 , wherein the nucleic acid sequence encoding the bispecific antibody and the nucleic acid sequence encoding 4-1BB ligand are cDNA.

3. A composition comprising the isolated MSC of claim 1 .

4. The composition of claim 3 , further comprising a pharmaceutically acceptable carrier.

5. The isolated MSC of claim 1 , wherein the V L antibody domain and V H antibody domain comprise the amino acid sequences of SEQ ID NO: 3, 4, and 5, and the V L antibody domain and V H antibody domain comprise the amino acid sequences of 6, 7, and 8.

Assignments (3)
CHANGE OF NAME Recorded May 26, 2022
From: GEMOAB GMBH
To: AVENCELL EUROPE GMBH
Reel/Frame 060202/0628 →
CHANGE OF NAME Recorded Nov 23, 2021
From: GEMOAB MONOCLONALS GMBH
To: GEMOAB GMBH
Reel/Frame 058566/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2015
From: EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 037319/0053 →
Priority Claims (1)
EP 15166347 · May 5, 2015 · regional
Continuity (2)
Provisional Application 62088578 · Dec 6, 2014
Related Publication 20160159909A1 · Jun 9, 2016